WHO WE ARE ?

A strong inter-disciplinary team with competencies in Entrepreneurship, Mathematics, Engineering, IT, Biochemistry, Microbiology, Molecular Biology, Pharmacology and Medicinal Chemistry.

 

WHAT WE DO ?

Engineering a new class of antibiotics targeting Gram Negative Bacteria

We aim to be the premier innovator of safe, effective and robust antibiotics that target Gram-negative bacteria

Our antibiotics are designed to be significantly immune to bacterial resistance and work on all known forms of drug resistant bacteria
 
 

WHY WE DO ?

• Centers for Disease Control (CDC) estimates that 1 in 25 patients worldwide will acquire an infection as a result of their hospital stay
• 10 million deaths will occur worldwide if antibiotic resistance is left unchecked, costing the world $100 trillion by 2050
• The antibiotic pipeline lack new mechanisms against drug resistant Gram negative bacteria